On this page
CORDRAN
Flurandrenolide · Cream
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Flurandrenolide | .5 mg/g | 197719 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 012806-001 | CORDRAN | OINTMENT | FLURANDRENOLIDE | Discontinued | AT | RLD | |
| 012806-002 | CORDRAN SP | CREAM | FLURANDRENOLIDE | Discontinued | — | RLD | |
| 012806-003 | CORDRAN SP | CREAM | FLURANDRENOLIDE | Discontinued | — | RLD | |
| 012806-004 | CORDRAN | OINTMENT | FLURANDRENOLIDE | Discontinued | — | RLD |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 37 | Manufacturing (CMC) | Approved | July 23, 2013 | Standard |
| Supplement | 36 | Manufacturing (CMC) | Approved | June 12, 2013 | Standard |
| Supplement | 35 | Manufacturing (CMC) | Approved | December 14, 2012 | Standard |
| Supplement | 32 | Manufacturing (CMC) | Approved | March 25, 2008 | N/A |
| Supplement | 28 | Manufacturing (CMC) | Approved | July 17, 2002 | Standard |
| Supplement | 27 | Manufacturing (CMC) | Approved | November 6, 1998 | Standard |
| Supplement | 26 | Manufacturing (CMC) | Approved | August 30, 1991 | Standard |
| Supplement | 25 | Manufacturing (CMC) | Approved | October 2, 1990 | Standard |
| Supplement | 24 | Manufacturing (CMC) | Approved | December 18, 1987 | Standard |
| Supplement | 23 | Manufacturing (CMC) | Approved | June 3, 1987 | Standard |
| Supplement | 22 | Labeling | Approved | November 14, 1986 | — |
| Supplement | 21 | Labeling | Approved | October 8, 1982 | — |
| Supplement | 20 | Labeling | Approved | August 12, 1980 | — |
| Supplement | 19 | Manufacturing (CMC) | Approved | November 26, 1979 | Standard |
| Supplement | 16 | Labeling | Approved | July 24, 1978 | — |
| Supplement | 17 | Labeling | Approved | June 30, 1978 | — |
| Supplement | 15 | Manufacturing (CMC) | Approved | December 14, 1977 | Standard |
| Supplement | 13 | Manufacturing (CMC) | Approved | November 11, 1977 | Standard |
| Supplement | 14 | Labeling | Approved | February 23, 1977 | — |
| Original application | 1 | Type 1 - New Molecular Entity | Approved | October 18, 1965 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250707). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Cordran® (flurandrenolide, USP) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION For moist lesions, a small quantity of the cream should be rubbed gently into the affected areas 2 or 3 times a day. Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Cordran® (flurandrenolide, USP) should not be used with occlusive dressings unless directed by a physician. Tight-fitting diapers or plastic pants may constitute occlusive dressings.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneform eruptions Hypopigmentation Perioral dermatitis Allergic contact dermatitis The following may occur more frequently with occlusive dressings: Maceration of the skin Secondary infection Skin atrophy Striae Miliaria Postmarketing Adverse Reactions The following adverse reactions have been identified during post approval use of flurandrenolide, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin : skin striae, hypersensitivity, skin atrophy, contact dermatitis and skin discoloration.
Description
openFDA Drug LabelingDESCRIPTION Cordran® (flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy, crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in ether. One gram of flurandrenolide dissolves in 72 mL of alcohol and in 10 mL of chloroform. The molecular weight of flurandrenolide is 436.52. The chemical name of flurandrenolide is Pregn-4-ene-3,20-dione, 6-fluoro-11,21-dihydroxy- 16,17-[(1-methylethylidene)bis (oxy)]-, (6α, 11β, 16α)-; its empirical formula is C 24 H 33 FO 6 . The structure is as follows: Each gram of Cordran® Cream (flurandrenolide Cream, USP) contains 0.5 mg (1.145 μmol; 0.05%) flurandrenolide in an emulsified base composed of cetyl alcohol, citric acid, mineral oil, polyoxyl 40 stearate, propylene glycol, sodium citrate, stearic acid, and purified water. Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Cordran® Cream is supplied in aluminum tubes as follows: Flurandrenolide Cream, USP 0.05%: 60 g (NDC 74157-180-60) 120 g (NDC 74157-130-07) Keep out of reach of children. Storage Keep tightly closed. Protect from light. Store at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F) [See USP controlled room temperature].
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: FLURANDRENOLIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 74157-130-07 | 74157-130 | INA Pharmaceutics, Inc | 1 TUBE in 1 CARTON (74157-130-07) / 120 g in 1 TUBE | July 7, 2025 |
| 74157-180-60 | 74157-180 | INA Pharmaceutics, Inc | 1 TUBE in 1 CARTON (74157-180-60) / 60 g in 1 TUBE | July 7, 2025 |
| 74157-130 | 74157-130 | INA Pharmaceutics, Inc | — | July 7, 2025 |
| 74157-180 | 74157-180 | INA Pharmaceutics, Inc | — | July 7, 2025 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.